Mechanism Of Action:
Crizotinib is a tyrosine kinase receptor inhibitor. It inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteur d’Origine Nantais (RON). Abnormalities in the ALK gene caused by mutations or translocations can lead to expression of oncogenic fusion proteins. In patients with NSCLC, they have the EML4-ALK gene. It can inhibit ALK tyrosine kinase which ultimately results in decreased proliferation of cells that carry the genetic mutation and tumor survivability.
It is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK or a gene called ROS1.